People with a history of certain types of cancer may be at increased risk of melanoma—an aggressive form of skin cancer. These results were published in the Archives of Dermatology. Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve melanoma. More than 8,000... Continue Reading

According to a combined analysis of previous studies, there is still no clear evidence that vitamin D supplements reduce the risk of cancer. The combination of vitamin D and calcium, however, does appear to reduce the risk of bone fractures in older people. These results were published in the Annals... Continue Reading

Children born to survivors of childhood cancer do not appear to have an increased risk of birth defects. These results were published in the Journal of Clinical Oncology. Cancer treatment can have a range of reproductive effects. Treatment may result in a loss or reduction of fertility in men and women,... Continue Reading

Among adults with low platelet counts or bleeding symptoms from primary immune thrombocytopenia (ITP), treatment with Nplate® (romiplostim) produces a rapid increase in platelet counts. These results were presented at the 53rd Annual Meeting of the American Society of Hematology. Thrombocytopenia occurs... Continue Reading

People with myotonic muscular dystrophy may be more likely than people in the general population to develop certain types of cancer. These results were published in the Journal of the American Medical Association. Myotonic muscular dystrophy (MMD) is the most common form of adult-onset muscular dystrophy.... Continue Reading

Final results from the VISTA trial demonstrate that the addition of Velcade® (bortezomib) to melphalan and prednisone substantially improves overall survival among patients with previously untreated multiple myeloma. These results were presented at the 53rd Annual Meeting of the American Society of... Continue Reading

Among women with metastatic, HER2-positive breast cancer, treatment with a combination of HER2-targeted therapies may produce better outcomes than treatment with only a single HER2-targeted therapy. These results were published in the New England Journal of Medicine and were also presented at the 2011... Continue Reading

Among postmenopausal women with advanced breast cancer that had become resistant to hormonal therapy, the combination of Afinitor® (everolimus) and Aromasin® (exemestane) delayed cancer progression to a greater extent than Aromasin alone. The results of this Phase III clinical trial were presented... Continue Reading

Longer-term follow-of of the ABCSG-12 study continues to suggest that the bisphosphonate drug Zometa® (zoledronic acid) may improve outcomes among women with early-stage, hormone receptor-positive breast cancer. These results were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The... Continue Reading

Less than one-quarter of women who have a mastectomy undergo immediate breast reconstruction. These results were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. For some women with breast cancer, treatment will include a single or double mastectomy (removal of one or both breasts).... Continue Reading

Having diabetes or being obese after the age of 60 increases a woman’s risk of getting breast cancer. These results were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. Diabetes affects almost 26 million people in the United States and is the seventh leading cause of death.[1]... Continue Reading

Among women with early-stage breast cancer, use of brachytherapy to administer radiation therapy may result in more post-operative complications than conventional external beam radiation therapy, and may also increase the likelihood that a woman will later require a mastectomy. These results were presented... Continue Reading